Between-Group Differences
MDD, Depression, Anxiety, depressive disorder
SECONDARY, REMISSION
The demographic information and baseline clinical scores of the 3 classes were compared. Group differences were found in age (χBaseline Demographic and Clinical Characteristics in Identified Latent Trajectories in MDD Patients Receiving ECT TreatmentAbbreviations: BMI, body mass index; BZDs, benzodiazepines; CGI, Clinical Global Impression; ECT, electroconvulsive therapy; FDR, false discover rate; HAMA, Hamilton Anxiety Scale; HAMD, Hamilton Depression Scale-17; MDD, major depressive disorder; MMSE, Mini-Mental State Examination; NaSSAs: noradrenergic and selective serotonergic antidepressants; NDRIs, norepinephrine and dopamine reuptake inhibitors; non-BZDs, nonbenzodiazepine; SARIs, serotonin antagonists and reuptake inhibitors; SNRIs, serotonin and norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.For the secondary outcomes, there were significant differences between the 3 classes in the remission rate at week 2, week 3, and week 4 (week 2: χHAMD Remission Rates for the 3 Latent Trajectories in MDD Patients Receiving ECT Treatment